Where I'd invest $2,500 in ASX shares today

It's hard to know which ASX shares to buy and which to avoid in the current market, so here are a couple of blue chips on my list today.

| More on:
3 piggy banks increasing in size, asx shares financials, growth, asx portfolio

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's hard to know where to invest in ASX shares right now. The S&P/ASX 200 Index (ASX: XJO) has roared back to life after the bear market slump in February and March.

There's so much uncertainty around the economy with monetary and fiscal policy fighting against the impending Aussie recession.

With all that's going on, here's where I'd be looking to invest $2,500 right now.

How to invest $2,500 in ASX shares today

I'm a big believer of the old mantra, 'time in the market beats timing the market'. Essentially this means that you shouldn't overthink the current market if you're investing for the long-term.

The ASX 200 has historically trended upwards which is good news for buy and hold investors.

I think buying high-quality ASX shares is the key to long-term wealth.

This means I'm looking at some of the good value, blue chip shares today. For instance, the BHP Group Ltd (ASX: BHP) share price is one I've got my eye on.

BHP shares have fallen lower in 2020 but could be due for a rebound. Strong commodity prices may persist for the rest of 2020 and beyond if we see a global infrastructure boom.

That's good news for the ASX mining share and its earnings. But it's not just the mining sector that could be set to gain this year.

It's hard to ignore the healthcare sector amid the coronavirus pandemic. Healthcare companies generally have non-cyclical earnings and some defensive exposure is often a good thing.

This means I'd be looking at an ASX healthcare share like CSL Limited (ASX: CSL).

CSL shares have slumped below the $300 per share mark in recent weeks. This could present a buying opportunity if you're bullish on the Aussie biotech's long-term success.

I think CSL has a strong research and development pipeline as well as a competitive advantage in both its influenza vaccinations and blood plasma segments.

This could mean the ASX healthcare share is due for a rebound back towards the $300 mark and beyond in 2020.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »